Reducing risk in smokers

Current Opinion in Pulmonary Medicine

Volumn 10, Issue 4, 2004, Pages 284-288

  Westmaas, J Lee ^a   Brandon, Thomas H ^b,c  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cessation; Lung cancer; Nicotine; Smoking

Indexed keywords

AMFEBUTAMONE; CANNABINOID RECEPTOR ANTAGONIST; NICOTINE; NICOTINE GUM; RIMONABANT; UNCLASSIFIED DRUG;

CANCER RISK; CIGARETTE SMOKING; CLINICAL TRIAL; EXPOSURE; HUMAN; LUNG CARCINOMA; NICOTINE REPLACEMENT THERAPY; PATIENT CARE; REVIEW; RISK REDUCTION; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE;

EID: 3042578374     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcp.0000128431.72268.4d     Document Type: Review

References (54)

1. Centers for Disease Control and Prevention: Reducing the health consequences of smoking: 25 years of progress - a report of the Surgeon General. Washington, DC: US Department of Health and Human Services, Public Health Service, Centers for Disease Control; 1989, DHHS Publication No. (CDC) 89-8411.
2. Ebbert JO, Yang P, Vachon CM, et al.: J Clin Oncol 2003, 21:921-926. This study examines risk reduction according to histologic cell type and years of abstinence.
3. Ando M, Wakai K, Seki N, et al.: Attributable and absolute risk of lung cancer death by smoking status: findings from the Japan Collaborative Cohort Study. Int J Cancer 2003, 105:249-254.
4. Tammemagi CM, Neslund-Dudas C, Simoff M, et al.: Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004, 125:27-37.
5. Halpern MT, Gillespie BW, Warner KE: Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1993, 17:457-464.
6. Weinstein ND: Accuracy of smokers'risk perceptions. Ann Behav Med 1998, 20:135-140.
7. McBride CM, Halabi S, Bepler G, et al.: Maximizing the motivational impact of feedback of lung cancer susceptibility on smokers' desire to quit. J Health Commun 2000, 5:229-241.
8. Lerman C, Gold K, Audrain J, et al.: Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change. Health Psychol 1997, 16:87-99.
9. Walker WB, Franzini LR: Low-risk aversive group treatments, physiological feedback, and booster sessions for smoking cessation. Beh Ther 1985, 16:263-274.
10. Lipkus IM, McBride CM, Pollak KI, et al.: Interpretation of genetic risk feedback among African American smokers with low socioeconomic status. Health Psychol 2004, 23:178-188.
11. Woicik PB, Westmaas JL, Vitulli D: Biomarker feedback and smokers' perception of health risk: effects of threat and reward sensitivities. Poster presented at the 2003 Annual Meeting of the American Society of Preventive Oncology, Philadelphia.
12. Richardson GE, Tucker MA, Venzon DJ, et al.: Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993, 119:383-390.
13. Kawahar M, Ushijima S, Kamimori T, et al.: Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br J Cancer 1998, 78:409-412.
14. Videtic GMM, Stitt LW, Dar AR, et al.: Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003, 21:1544-1549.
15. Rigotti NA, Munafo MR, Murphy MF, et al.: Interventions for smoking cessation in hospitalized patients. Cochrane Database Syst Rev 2003, 1:CD001837. Provides an excellent, detailed, and comprehensive review of the efficacy of randomized and quasirandomized smoking cessation interventions with patients.
16. Copeland AL, Brandon TH: Intervening with the tobacco-dependent patient. J Clin Outcomes Management 2001, 8:43-51.
17. Cromwell J, Bartosch WJ, Fiore MC, et al.: Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA 1997, 278:1759-1766.
18. Levinson AH, Perez-Stable EJ, Espinoza P, et al: Latinos report less use of pharmaceutical aids when trying to quit smoking. Am J Prev Med 2004, 26:105-111.
19. Silagy C, Lancaster T, Stead L, et al.: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2002.
20. Fiore MC, Bailey WC, Cohen SJ, et al.: Treating tobacco use and dependence: clinical practice guideline. Rockville, MD: US Department of Health and Human Services: Public Health Service, 2000.
21. Pierce JP, Gilpin MS: Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002, 288:1260-1264.
22. Shiffman S, Hughes JR, Pillitteri JL, et al.: Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample. Tob Control 2003, 12:310-316.
23. Paul CL, Walsh RA, Girgis A: Nicotine replacement therapy products over the counter: real-life use in the Australian community. Aust N Z J Public Health 2003, 27:491-495.
24. Hudmon KS, Hemberger KK, Corelli RL, et al.: The pharmacist's role in smoking cessation counseling: perceptions of users of nonprescription nicotine replacement therapy. J Am Pharm Assoc 2003, 43:573-582.
25. Hughes JR, Shiffman S, Callas P, et al.: A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 2003, 12:21-27.
26. Hasford J, Fagerstrom KO, Haustein KO: A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. Cohort study on smoking cessation. Eur J Clin Pharmacol 2003, 59:443-447.
27. Kassel JD, Stroud LR, Paronis CA: Smoking, stress, and negative affect: correlation, causation, and context across stages of smoking. Psych Bull 2003, 129:270-304.
28. Slemmer RD, Madras BK, Bergman J: Effects of cocaine and related drugs in nonhuman primates: II. Stimulant effects on schedule-controlled behavior. J Pharmacol Exp Ther 2000, 251:321-327.
29. Fryer JD, Lukas RJ: Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999, 288:88-92.
30. Rauhut AS, Neugebauer N, Dwoskin LP, et al.: Effect of bupropion on nicotine self-administration in rats. Psychopharmacology 2003, 169:1-9.
31. Hughes JR, Stead LF, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2002, CD000031.
32. Richmond R, Zwar N: Review of bupropion for smoking cessation. Drug Alcohol Rev 2003, 22:203-220.
33. Tonstad S, Farsang C, Klaene G, et al.: Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multi-centre, randomized study. Eur Heart J 2003, 24:946-955.
34. West R: Bupropion SR for smoking cessation. Expert Opin Pharmacother 2003, 4:533-540.
35. Tonesen P, Tonstad S, Hjalmarson A, et al.: A multicentre, randomized, double-blind placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 2003, 254:184-192.
36. Jorenby D: Clinical efficacy of bupropion in the management of smoking cessation. Drugs 2002, 62(Suppl 2):25-35.
37. Hurt RD, Sachs DPL, Glover ED, et al.: A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997, 337:1195-1202.
38. Martinez-Raga J, Keaney F, Sutherland G, et al.: Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile. Addict Biol 2003, 8:13-21.
39. Collins B, Wileyto P, Patterson F, et al.: Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res 2004, 6:27-37.
40. Hays JT, Ebbert JO: Bupropion sustained release for treatment of tobacco dependence. Mayo Clin Proc 2003, 78:1020-1024.
41. Etter J-F, Kozlowski LT, Perneger TV: What smokers believe about light and ultralight cigarettes. Prev Med 2003, 36:92-98.
42. Gilpin EA, Emery S, White MM, et al.: Does tobacco industry marketing of "light" cigarettes give smokers a rationale for postponing quitting? Nicotine Tob Res 2002, 4(Suppl 2):S147-S155.
43. Benowitz N: Compensatory smoking of low-yield cigarettes. In: NCl smoking and tobacco control monograph 13: Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Edited by Shopland DR, Burns DM, Benowitz JL, Amacher RH. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute 2001:39-64.
44. Thun MJ, Lally CA, Flannery JT, et al.: Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997, 89:1580-1586.
45. Levi F, Franceschi S, LaVecchia C, et al.: Lung cancer carcinoma trends by histologic type in Vaud and Neuchatel, Switzerland, 1974-1994. Cancer 1997, 79:906-914.
46. Harris JE, Thun MJ, Mondul AM, et al.: Cigarette tar yields in relation to mortality from lung cancer in the cancer prevention study II prospective cohort, 1982-8. Br Med J 2004, 328:72-75. This study is notable for its large sample and the breadth of control variables it assessed.
47. Slade J, Connolly GN, Lymperis D: Eclipse: does it live up to its health claims? Tob Control 2002, 11(Suppl 2):ii64-ii70.
48. Breland AB, Acosta MC, Eissenberg T: Tobacco specific nitrosamines and potential reduced exposure products for smokers: a preliminary evaluation of Advance. Tob Control 2003, 12:317-321.
49. Hatsukami DK, Lemmonds C, Tomar SL: Smokeless tobacco use: harm reduction or induction approach? Prev Med 2003, 38:309-317. A thorough and interesting analysis of the debate surrounding the use of smokeless tobacco as a harm reduction strategy.
50. Lewin F, Norell S, Johansson H, et al.: Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck. Cancer 1998, 82:1367-1374.
51. Schildt E, Eriksson M, Hardell L, et al.: Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study. Int J Cancer 1998, 77:341-346.
52. Feil EG, Noell J, Lichtenstein E, et al.: Evaluation of an internet-based smoking cessation program: lessons learned from a pilot study. Nicotine Tob Res 2003, 5:189-194.
53. Brandon TH, Collins BN, Juliano LM, et al.: Preventing relapse among former smokers: a comparison of minimal interventions via telephone and mail. J Consul Clin Psychol 2000, 68:103-113.
54. Brandon TH, Meade CD, Herzog TA, et al.: Efficacy and cost-effectiveness of a minimal intervention to prevent smoking relapse: dismantling the effects of content versus contact. J Consul Clin Psychol, in press.